Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Olmutinib (HM61713, BI 1482694) is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild-type form.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 33.00 | |
5 mg | In stock | $ 52.00 | |
10 mg | In stock | $ 81.00 | |
25 mg | In stock | $ 139.00 | |
50 mg | In stock | $ 189.00 | |
100 mg | In stock | $ 297.00 | |
200 mg | In stock | $ 486.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 54.00 |
Description | Olmutinib (HM61713, BI 1482694) is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild-type form. |
Targets&IC50 | BTK:13.9 nM |
In vitro | HM61713 causes potent inhibition in cell lines H1975 (L858R and T790M) and HCC827 (exon 19 deletion). It has a low potency for NSCLC cell line H358 harboring wild-type EGFR (GI50 of 2225 nM)[1]. |
In vivo | HM61713 has a half-life of over 24 h for EGFR inhibition. In the in vivo studies of xenograft models with grafts of H1975 and HCC827, HM61713 is active against the tumors without showing any side effects[1]. |
Synonyms | HM61713, BI 1482694, BI 1482694, HM61713 |
Molecular Weight | 486.59 |
Formula | C26H26N6O2S |
CAS No. | 1353550-13-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 22 mg/mL (45.2 mM)
DMSO: 90 mg/mL (185 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Olmutinib 1353550-13-6 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR BTK 1802181-20-9 HM-61713 ErbB-1 HM61713, BI 1482694 BI1482694 inhibit HM61713, BI1482694 BI-1482694 HER1 HM61713, BI-1482694 Epidermal growth factor receptor Inhibitor HM 61713 BI 1482694 HM61713 inhibitor